Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer

Abstract Background For advanced non‐small cell lung cancer (NSCLC), combination therapies including a PD‐1 inhibitor plus chemotherapy or a PD‐1 inhibitor, CTLA‐4 inhibitor, and chemotherapy are standard first‐line options. However, data directly comparing these regimens are lacking. This study com...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Thoracic Cancer
المؤلفون الرئيسيون:	Ayami Kaneko, Nobuaki Kobayashi, Kenji Miura, Hiromi Matsumoto, Kohei Somekawa, Tomofumi Hirose, Yukihito Kajita, Anna Tanaka, Shuhei Teranishi, Yu Sairenji, Hidetoshi Kawashima, Kentaro Yumoto, Toshinori Tsukahara, Nobuhiko Fukuda, Ryuichi Nishihira, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Makoto Kudo, Naoki Miyazawa, Takeshi Kaneko
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2024-05-01
الموضوعات:	ipilimumab nivolumab non‐small cell lung cancer pembrolizumab real‐world evidence
الوصول للمادة أونلاين:	https://doi.org/10.1111/1759-7714.15304